Anison Therapeutics is a preclinical-stage biotechnology company focused on developing innovative topical therapeutics for diseases associated with the Human Papillomavirus (HPV). We fight the HPV with a new treatment that targets-not the symptoms-but the root cause of the virus. Our initial focus is on formulating and commercializing topical treatments to address the unmet needs concerning genital warts and premalignant infections caused by HPV. Eventually, we aim to extend our focus on the treatment of a broader spectrum of warts and diseases driven by HPV.
By 2024, we anticipate initiating the preclinical phase of our pharmaceutical product development. Over the past year, our achievements include demonstrating API production feasibility, conducting light GMP production, creating prototypes, and performing proof of concept studies for our product. These significant milestones have set the stage for our next step: the preclinical program.
Our dedicated team with deep expertise in business, science, and commercialization of innovations, is committed to bringing our targeted HPV solutions to the market to address these widespread medical challenges effectively.